Enzo Biochem INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
Enzo Biochem Director Bradley Louis Radoff disposed of all his direct and indirect holdings in the company following its merger with Bethpage Parent, Inc. for $0.70 per share.
Enzo Biochem Director Steven J. Pully disposed of all his shares and restricted stock units following the company's merger, receiving $0.70 per share in cash.
ENZO Biochem's Chief Financial Officer, Patricia Eckert, reported the disposition of common stock and cancellation of stock options following the company's merger with Bethpage Parent, Inc.
Enzo Biochem Director Jonathan Couchman disposed of all his direct and indirect holdings in the company, totaling 605,134 shares and RSUs, following the completion of the merger with Bethpage Parent, Inc. at $0.70 per share.
ENZO BIOCHEM's CEO, Kara Cannon, reported the disposition of common stock and cancellation of stock options following the company's merger with Bethpage Parent, Inc. for $0.70 per share.
Director Bradley Louis Radoff of Enzo Biochem acquired 142,897 shares through restricted stock units, increasing his total holdings.
Director Steven J. Pully of Enzo Biochem, Inc. was granted 142,897 restricted stock units, which will vest on the first anniversary of the grant date or upon a change of control event.
Enzo Biochem director Jonathan Couchman acquired 142,897 shares of common stock through restricted stock units, according to a recent SEC filing.
Patricia Eckert, CFO of Enzo Biochem, Inc., reports the acquisition of 100,000 stock options in the company.
Kara Cannon, CEO of Enzo Biochem, reports the withholding of shares to cover tax obligations after the vesting of restricted stock units.
Kara Cannon, CEO of Enzo Biochem, Inc., reports the acquisition of 200,000 stock options exercisable at $2, vesting in three equal annual installments starting May 23, 2025.
Kara Cannon, CEO of Enzo Biochem, reports acquisition and disposal of company stock, including shares from vested performance awards and restricted stock units.
Patricia Eckert, CFO of Enzo Biochem, Inc., was granted 75,000 stock options on February 23, 2024, according to a Form 4 filing with the SEC.